_id
6911baaeccc777a4e85d6180
Ticker
GDTC
Name
CytoMed Therapeutics Limited Ordinary Shares
Exchange
NASDAQ
Address
1 Commonwealth Lane, Singapore, Singapore, 149544
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://w2.cytomed.sg
Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Last Close
1.38
Volume
5661
Current Price
1.4001
Change
0.055
Last Updated
2026-01-03T12:27:52.645Z
Image
data:image/webp;base64,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
Ipo Date
2023-04-14T00:00:00.000Z
Market Cap
22528726
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
5
Target Price
5
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
105705
Cost Of Revenue
7326
Gross Profit
98379
Operating Expenses
608930
Operating Income
-510551
Interest Expense
7788
Pretax Income
-883113
Net Income
-882300
Eps
-0.0747125370990552
Dividends Per Share
-
Shares Outstanding
11733712
Income Tax Expense
-
EBITDA
-804323
Operating Margin
-482.99607397947113
Total Other Income Expense Net
-372561
Cash
2245275
Short Term Investments
-
Receivables
965907
Inventories
-
Total Current Assets
3211183
Property Plant Equipment
2731179
Total Assets
6572398
Payables
375678
Short Term Debt
45483
Long Term Debt
-
Total Liabilities
892509
Equity
5620369
Bs_currency_symbol
-
Depreciation
70567
Change In Working Capital
-71614
Cash From Operations
-1162901
Capital Expenditures
136762
Cash From Investing
-276442
Cash From Financing
-18553
Net Change In Cash
-1201521
Cf_currency_symbol
-
PE
-
PB
2.9418262619945414
ROE
-15.698257534336268
ROA
-13.424323968207647
FCF
-1299663
Fcf Percent
-12.295189442315879
Piotroski FScore
0
Health Score
34
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
3
Growth Investing Score
1.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
4
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
105705
Quarters > 0 > income Statement > cost Of Revenue
7326
Quarters > 0 > income Statement > gross Profit
98379
Quarters > 0 > income Statement > operating Expenses
608930
Quarters > 0 > income Statement > operating Income
-510551
Quarters > 0 > income Statement > interest Expense
7788
Quarters > 0 > income Statement > pretax Income
-883113
Quarters > 0 > income Statement > net Income
-882300
Quarters > 0 > income Statement > eps
-0.0747125370990552
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
11809263
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-804323
Quarters > 0 > income Statement > operating Margin
-482.99607397947113
Quarters > 0 > income Statement > total Other Income Expense Net
-372561
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
2245275
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
965907
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
3211183
Quarters > 0 > balance Sheet > property Plant Equipment
2731179
Quarters > 0 > balance Sheet > total Assets
6572398
Quarters > 0 > balance Sheet > payables
375678
Quarters > 0 > balance Sheet > short Term Debt
45483
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
892509
Quarters > 0 > balance Sheet > equity
5620369
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-882300
Quarters > 0 > cash Flow > depreciation
70567
Quarters > 0 > cash Flow > change In Working Capital
-71614
Quarters > 0 > cash Flow > cash From Operations
-1162901
Quarters > 0 > cash Flow > capital Expenditures
136762
Quarters > 0 > cash Flow > cash From Investing
-276442
Quarters > 0 > cash Flow > cash From Financing
-18553
Quarters > 0 > cash Flow > net Change In Cash
-1201521
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.0747125370990552
Quarters > 0 > ratios > PB
2.9418262619945414
Quarters > 0 > ratios > ROE
-15.698257534336268
Quarters > 0 > ratios > ROA
-13.424323968207647
Quarters > 0 > ratios > FCF
-1299663
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-12.295189442315879
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
100043
Quarters > 1 > income Statement > cost Of Revenue
6934
Quarters > 1 > income Statement > gross Profit
93110
Quarters > 1 > income Statement > operating Expenses
576314
Quarters > 1 > income Statement > operating Income
-483205
Quarters > 1 > income Statement > interest Expense
3836
Quarters > 1 > income Statement > pretax Income
-835812
Quarters > 1 > income Statement > net Income
-835042
Quarters > 1 > income Statement > eps
-0.0707107632372994
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
11809263
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-761242
Quarters > 1 > income Statement > operating Margin
-482.9973111562028
Quarters > 1 > income Statement > total Other Income Expense Net
-352606
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
2125015
Quarters > 1 > balance Sheet > short Term Investments
200351
Quarters > 1 > balance Sheet > receivables
914171
Quarters > 1 > balance Sheet > inventories
614204
Quarters > 1 > balance Sheet > total Current Assets
3039187
Quarters > 1 > balance Sheet > property Plant Equipment
2584893
Quarters > 1 > balance Sheet > total Assets
6220369
Quarters > 1 > balance Sheet > payables
355556
Quarters > 1 > balance Sheet > short Term Debt
43047
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
844704
Quarters > 1 > balance Sheet > equity
5319333
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-835042
Quarters > 1 > cash Flow > depreciation
66788
Quarters > 1 > cash Flow > change In Working Capital
-67778
Quarters > 1 > cash Flow > cash From Operations
-595148
Quarters > 1 > cash Flow > capital Expenditures
129437
Quarters > 1 > cash Flow > cash From Investing
-8398
Quarters > 1 > cash Flow > cash From Financing
-12977
Quarters > 1 > cash Flow > net Change In Cash
-979701
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.0707107632372994
Quarters > 1 > ratios > PB
3.1083124756994907
Quarters > 1 > ratios > ROE
-15.698246377882342
Quarters > 1 > ratios > ROA
-13.424316145874949
Quarters > 1 > ratios > FCF
-724585
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-7.242735623681817
Quarters > 1 > health Score
30
Quarters > 2 > quarter
2024-09-30
Quarters > 2 > income Statement > revenue
108617
Quarters > 2 > income Statement > cost Of Revenue
11220
Quarters > 2 > income Statement > gross Profit
97398
Quarters > 2 > income Statement > operating Expenses
495222
Quarters > 2 > income Statement > operating Income
-397825
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-557628
Quarters > 2 > income Statement > net Income
-555676
Quarters > 2 > income Statement > eps
-0.04815191602123386
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
11540060
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-512668
Quarters > 2 > income Statement > operating Margin
-366.264028651132
Quarters > 2 > income Statement > total Other Income Expense Net
-159802
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
3867418
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
14614
Quarters > 2 > balance Sheet > inventories
652685
Quarters > 2 > balance Sheet > total Current Assets
4669117
Quarters > 2 > balance Sheet > property Plant Equipment
2531179
Quarters > 2 > balance Sheet > total Assets
7833665
Quarters > 2 > balance Sheet > payables
30060
Quarters > 2 > balance Sheet > short Term Debt
35723
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
796737
Quarters > 2 > balance Sheet > equity
6976431
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-555676
Quarters > 2 > cash Flow > depreciation
65552
Quarters > 2 > cash Flow > change In Working Capital
-46852
Quarters > 2 > cash Flow > cash From Operations
-604600
Quarters > 2 > cash Flow > capital Expenditures
190676
Quarters > 2 > cash Flow > cash From Investing
1172718
Quarters > 2 > cash Flow > cash From Financing
-13752
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.04815191602123386
Quarters > 2 > ratios > PB
2.3159747449663013
Quarters > 2 > ratios > ROE
-7.965046884287968
Quarters > 2 > ratios > ROA
-7.093435831121194
Quarters > 2 > ratios > FCF
-795276
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-7.321837281456862
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-06-30
Quarters > 3 > income Statement > revenue
82667
Quarters > 3 > income Statement > cost Of Revenue
123874
Quarters > 3 > income Statement > gross Profit
81853
Quarters > 3 > income Statement > operating Expenses
1269724
Quarters > 3 > income Statement > operating Income
-1393602
Quarters > 3 > income Statement > interest Expense
7278
Quarters > 3 > income Statement > pretax Income
-808069
Quarters > 3 > income Statement > net Income
-807960
Quarters > 3 > income Statement > eps
-0.07001624318607703
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
11539608
Quarters > 3 > income Statement > income Tax Expense
569042
Quarters > 3 > income Statement > EBITDA
-688745
Quarters > 3 > income Statement > operating Margin
-1685.8020733787364
Quarters > 3 > income Statement > total Other Income Expense Net
585533
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
4772812
Quarters > 3 > balance Sheet > short Term Investments
259023
Quarters > 3 > balance Sheet > receivables
295192
Quarters > 3 > balance Sheet > inventories
530171
Quarters > 3 > balance Sheet > total Current Assets
5684322
Quarters > 3 > balance Sheet > property Plant Equipment
1829133
Quarters > 3 > balance Sheet > total Assets
8045945
Quarters > 3 > balance Sheet > payables
33064
Quarters > 3 > balance Sheet > short Term Debt
27573
Quarters > 3 > balance Sheet > long Term Debt
390896
Quarters > 3 > balance Sheet > total Liabilities
552246
Quarters > 3 > balance Sheet > equity
7494510
Quarters > 3 > balance Sheet > currency_symbol
SGD
Quarters > 3 > cash Flow > net Income
-401344
Quarters > 3 > cash Flow > depreciation
61532
Quarters > 3 > cash Flow > change In Working Capital
15242
Quarters > 3 > cash Flow > cash From Operations
-865332
Quarters > 3 > cash Flow > capital Expenditures
335602
Quarters > 3 > cash Flow > cash From Investing
-1401380
Quarters > 3 > cash Flow > cash From Financing
-14651
Quarters > 3 > cash Flow > net Change In Cash
-2396316
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.07001624318607703
Quarters > 3 > ratios > PB
2.1557920612288193
Quarters > 3 > ratios > ROE
-10.780691466153224
Quarters > 3 > ratios > ROA
-10.041828523560625
Quarters > 3 > ratios > FCF
-1200934
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-14.527368841254672
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
52005
Annuals > 0 > income Statement > cost Of Revenue
22733
Annuals > 0 > income Statement > gross Profit
52380
Annuals > 0 > income Statement > operating Expenses
1871438
Annuals > 0 > income Statement > operating Income
-2626170
Annuals > 0 > income Statement > interest Expense
15199
Annuals > 0 > income Statement > pretax Income
-1887042
Annuals > 0 > income Statement > net Income
-1883178
Annuals > 0 > income Statement > eps
-0.16318934917088063
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
11539834
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-1790556
Annuals > 0 > income Statement > operating Margin
-5049.841361407557
Annuals > 0 > income Statement > total Other Income Expense Net
739128
Annuals > 0 > income Statement > currency_symbol
SGD
Annuals > 0 > balance Sheet > cash
3639401
Annuals > 0 > balance Sheet > short Term Investments
200351
Annuals > 0 > balance Sheet > receivables
13752
Annuals > 0 > balance Sheet > inventories
614204
Annuals > 0 > balance Sheet > total Current Assets
4393833
Annuals > 0 > balance Sheet > property Plant Equipment
2381944
Annuals > 0 > balance Sheet > total Assets
7371805
Annuals > 0 > balance Sheet > payables
28287
Annuals > 0 > balance Sheet > short Term Debt
33617
Annuals > 0 > balance Sheet > long Term Debt
394310
Annuals > 0 > balance Sheet > total Liabilities
749763
Annuals > 0 > balance Sheet > equity
6565112
Annuals > 0 > balance Sheet > currency_symbol
SGD
Annuals > 0 > cash Flow > net Income
-1842776
Annuals > 0 > cash Flow > depreciation
245558
Annuals > 0 > cash Flow > change In Working Capital
-57912
Annuals > 0 > cash Flow > cash From Operations
-1694595
Annuals > 0 > cash Flow > capital Expenditures
1025272
Annuals > 0 > cash Flow > cash From Investing
494589
Annuals > 0 > cash Flow > cash From Financing
-33357
Annuals > 0 > cash Flow > net Change In Cash
-1277237
Annuals > 0 > cash Flow > currency_symbol
SGD
Annuals > 0 > ratios > PE
-0.16318934917088063
Annuals > 0 > ratios > PB
2.4432742746810714
Annuals > 0 > ratios > ROE
-28.68462868569493
Annuals > 0 > ratios > ROA
-25.54568385897348
Annuals > 0 > ratios > FCF
-2719867
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-52.30010575906163
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
290560
Annuals > 1 > income Statement > cost Of Revenue
2824
Annuals > 1 > income Statement > gross Profit
381922
Annuals > 1 > income Statement > operating Expenses
1575288
Annuals > 1 > income Statement > operating Income
-3198938
Annuals > 1 > income Statement > interest Expense
38180
Annuals > 1 > income Statement > pretax Income
-3076730
Annuals > 1 > income Statement > net Income
-3131788
Annuals > 1 > income Statement > eps
-0.2946083400499551
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
10630344
Annuals > 1 > income Statement > income Tax Expense
486.17
Annuals > 1 > income Statement > EBITDA
-2937852
Annuals > 1 > income Statement > operating Margin
-1100.956084801762
Annuals > 1 > income Statement > total Other Income Expense Net
122208
Annuals > 1 > income Statement > currency_symbol
SGD
Annuals > 1 > balance Sheet > cash
6816200
Annuals > 1 > balance Sheet > short Term Investments
47190
Annuals > 1 > balance Sheet > receivables
204748
Annuals > 1 > balance Sheet > inventories
514320
Annuals > 1 > balance Sheet > total Current Assets
7650933
Annuals > 1 > balance Sheet > property Plant Equipment
1564609
Annuals > 1 > balance Sheet > total Assets
9372770
Annuals > 1 > balance Sheet > payables
18654
Annuals > 1 > balance Sheet > short Term Debt
30500
Annuals > 1 > balance Sheet > long Term Debt
407772
Annuals > 1 > balance Sheet > total Liabilities
852276
Annuals > 1 > balance Sheet > equity
8521218
Annuals > 1 > balance Sheet > currency_symbol
SGD
Annuals > 1 > cash Flow > net Income
-3131788
Annuals > 1 > cash Flow > depreciation
288822
Annuals > 1 > cash Flow > change In Working Capital
-3985
Annuals > 1 > cash Flow > cash From Operations
-2590580
Annuals > 1 > cash Flow > capital Expenditures
44174
Annuals > 1 > cash Flow > cash From Investing
-2106370
Annuals > 1 > cash Flow > cash From Financing
8164823
Annuals > 1 > cash Flow > net Change In Cash
3537086
Annuals > 1 > cash Flow > currency_symbol
SGD
Annuals > 1 > ratios > PE
-0.2946083400499551
Annuals > 1 > ratios > PB
1.7340453160569298
Annuals > 1 > ratios > ROE
-36.75282101690158
Annuals > 1 > ratios > ROA
-33.41368666893565
Annuals > 1 > ratios > FCF
-2634754
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-9.067848292951542
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
270335.15
Annuals > 2 > income Statement > cost Of Revenue
81034
Annuals > 2 > income Statement > gross Profit
-81034
Annuals > 2 > income Statement > operating Expenses
1615747
Annuals > 2 > income Statement > operating Income
-1696781
Annuals > 2 > income Statement > interest Expense
90773
Annuals > 2 > income Statement > pretax Income
-2269641
Annuals > 2 > income Statement > net Income
-2270655
Annuals > 2 > income Statement > eps
-0.28687631402303015
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
7915101
Annuals > 2 > income Statement > income Tax Expense
1189
Annuals > 2 > income Statement > EBITDA
-1095115
Annuals > 2 > income Statement > operating Margin
-627.6582974873966
Annuals > 2 > income Statement > total Other Income Expense Net
-572860
Annuals > 2 > income Statement > currency_symbol
SGD
Annuals > 2 > balance Sheet > cash
1179422
Annuals > 2 > balance Sheet > short Term Investments
11560
Annuals > 2 > balance Sheet > receivables
54536
Annuals > 2 > balance Sheet > inventories
430172
Annuals > 2 > balance Sheet > total Current Assets
1861924
Annuals > 2 > balance Sheet > property Plant Equipment
1847814
Annuals > 2 > balance Sheet > total Assets
3902536
Annuals > 2 > balance Sheet > payables
10921
Annuals > 2 > balance Sheet > short Term Debt
2795076
Annuals > 2 > balance Sheet > long Term Debt
468827
Annuals > 2 > balance Sheet > total Liabilities
3464804
Annuals > 2 > balance Sheet > equity
438241
Annuals > 2 > balance Sheet > currency_symbol
SGD
Annuals > 2 > cash Flow > net Income
-2337769
Annuals > 2 > cash Flow > depreciation
293315
Annuals > 2 > cash Flow > change In Working Capital
-108383
Annuals > 2 > cash Flow > cash From Operations
-1104855
Annuals > 2 > cash Flow > capital Expenditures
353736
Annuals > 2 > cash Flow > cash From Investing
-353370
Annuals > 2 > cash Flow > cash From Financing
793255
Annuals > 2 > cash Flow > net Change In Cash
-683723
Annuals > 2 > cash Flow > currency_symbol
SGD
Annuals > 2 > ratios > PE
-0.28687631402303015
Annuals > 2 > ratios > PB
25.104886101482972
Annuals > 2 > ratios > ROE
-518.129294155499
Annuals > 2 > ratios > ROA
-58.18408850040077
Annuals > 2 > ratios > FCF
-1458591
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-5.3954914852914975
Annuals > 2 > health Score
8
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
84178
Annuals > 3 > income Statement > cost Of Revenue
2590
Annuals > 3 > income Statement > gross Profit
81587
Annuals > 3 > income Statement > operating Expenses
937147
Annuals > 3 > income Statement > operating Income
-1398525
Annuals > 3 > income Statement > interest Expense
87580
Annuals > 3 > income Statement > pretax Income
-1533987
Annuals > 3 > income Statement > net Income
-1533987
Annuals > 3 > income Statement > eps
-0.2212005668781212
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
6934824
Annuals > 3 > income Statement > income Tax Expense
-53427.35
Annuals > 3 > income Statement > EBITDA
-1047759
Annuals > 3 > income Statement > operating Margin
-1661.3901494452232
Annuals > 3 > income Statement > total Other Income Expense Net
-128345
Annuals > 3 > income Statement > currency_symbol
SGD
Annuals > 3 > balance Sheet > cash
1863145
Annuals > 3 > balance Sheet > short Term Investments
11294
Annuals > 3 > balance Sheet > receivables
15222
Annuals > 3 > balance Sheet > inventories
320005
Annuals > 3 > balance Sheet > total Current Assets
2433318
Annuals > 3 > balance Sheet > property Plant Equipment
1850557
Annuals > 3 > balance Sheet > total Assets
4510018
Annuals > 3 > balance Sheet > payables
34292
Annuals > 3 > balance Sheet > short Term Debt
2005130
Annuals > 3 > balance Sheet > long Term Debt
539119
Annuals > 3 > balance Sheet > total Liabilities
2588418
Annuals > 3 > balance Sheet > equity
1921925
Annuals > 3 > balance Sheet > currency_symbol
SGD
Annuals > 3 > cash Flow > net Income
-1521239
Annuals > 3 > cash Flow > depreciation
244594
Annuals > 3 > cash Flow > change In Working Capital
-321143
Annuals > 3 > cash Flow > cash From Operations
-1270129
Annuals > 3 > cash Flow > capital Expenditures
431798
Annuals > 3 > cash Flow > cash From Investing
-610724
Annuals > 3 > cash Flow > cash From Financing
3094453
Annuals > 3 > cash Flow > net Change In Cash
1192876
Annuals > 3 > cash Flow > currency_symbol
SGD
Annuals > 3 > ratios > PE
-0.2212005668781212
Annuals > 3 > ratios > PB
5.015495068746179
Annuals > 3 > ratios > ROE
-79.81513326482563
Annuals > 3 > ratios > ROA
-34.01287977121156
Annuals > 3 > ratios > FCF
-1701927
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-20.2181924018152
Annuals > 3 > health Score
19
Valuation > metrics > PE
-0.0747125370990552
Valuation > metrics > PB
2.9418262619945414
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-15.698257534336268
Profitability > metrics > ROA
-27.475855471332526
Profitability > metrics > Net Margin
-8.34681424719739
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.1587990041223272
Risk > metrics > Interest Coverage
-65.55611196712891
Risk > final Score
-202
Risk > verdict
High
Liquidity > metrics > Current Ratio
7.624597244284252
Liquidity > metrics > Quick Ratio
7.624597244284252
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
48.916875243005094
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-444
Prev Risks > 1
25
Prev Risks > 2
-706
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:53:30.028Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-14
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.04
Earnings History > 0 > eps Difference
0.04
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-03-31
Earnings History > 1 > report Date
2025-04-28
Earnings History > 1 > date
2025-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.12
Earnings History > 1 > eps Estimate
-0.04
Earnings History > 1 > eps Difference
-0.08
Earnings History > 1 > surprise Percent
-200
Earnings History > 2 > period
2024-12-31
Earnings History > 2 > report Date
2024-12-31
Earnings History > 2 > date
2024-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-
Earnings History > 2 > eps Estimate
-0.04
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-09-30
Earnings History > 3 > report Date
2024-11-27
Earnings History > 3 > date
2024-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.04
Earnings History > 3 > eps Estimate
-0.04
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
0
Earnings History > 4 > period
2024-06-30
Earnings History > 4 > report Date
2024-09-30
Earnings History > 4 > date
2024-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.09
Earnings History > 4 > eps Estimate
-0.04
Earnings History > 4 > eps Difference
-0.05
Earnings History > 4 > surprise Percent
-125
Earnings History > 5 > period
2024-03-31
Earnings History > 5 > report Date
2024-05-29
Earnings History > 5 > date
2024-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
SGD
Earnings History > 5 > eps Actual
-0.04
Earnings History > 5 > eps Estimate
-0.04
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
0
Earnings History > 6 > period
2023-12-31
Earnings History > 6 > report Date
2024-02-28
Earnings History > 6 > date
2023-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
SGD
Earnings History > 6 > eps Actual
-0.05
Earnings History > 6 > eps Estimate
-0.05
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
0
Earnings History > 7 > period
2023-09-30
Earnings History > 7 > report Date
2023-11-17
Earnings History > 7 > date
2023-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
SGD
Earnings History > 7 > eps Actual
-0.08
Earnings History > 7 > eps Estimate
-0.06
Earnings History > 7 > eps Difference
-0.02
Earnings History > 7 > surprise Percent
-33.3333
Earnings History > 8 > period
2023-06-30
Earnings History > 8 > report Date
2023-08-30
Earnings History > 8 > date
2023-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
SGD
Earnings History > 8 > eps Actual
-0.06
Earnings History > 8 > eps Estimate
-0.06
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
0
Earnings History > 9 > period
2023-03-31
Earnings History > 9 > report Date
2023-05-31
Earnings History > 9 > date
2023-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
SGD
Earnings History > 9 > eps Actual
-0.06
Earnings History > 9 > eps Estimate
-0.06
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
0
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Closing: Is JanOne Inc stock a value trap - Market Trend Review & Weekly Setup with ROI Potential baoquankhu1.vn
Read more →CytoMed Therapeutics Outlines 2026 Clinical Plans and Seeks Shareholder Input on Patient-Access Scheme TipRanks
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
STRONG BUY
Target Price:
$5
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of CytoMed Therapeutics Limited Ordinary Shares
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
0
EPS Estimate
-0.04
EPS Difference
0.04
Surprise Percent
100%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.